The Core Group provides leadership and sets the strategic direction for the work of the New Diagnostics Working Group. The Core Group is designed to facilitate and accelerate decision-making, and to act as a catalyst to effective implementation of the Global Plan to End TB.
The Core Group is representative of the broad constituencies involved in the development and implementation of new TB diagnostics and consists of the following members:
|Academia:||Dr. Stefan Niemann, Borstel Research Institute, Germany|
|NGOs:||Dr. Martina Casenghi, Médecins Sans Frontières, Switzerland|
|WHO and GLI||Dr. Christopher Gilpin, WHO Global TB Programme, Switzerland|
|High-burden countries:||Dr. Camilla Rodrigues, Hinduja Hospital, India|
|Diagnostics Manufacturer:||Mr Philippe Jacon, Cepheid, France|